http://www.mises.org/story/2827By Jeffrey A. Tucker
Posted on 12/26/2007
There I stood at the pharmacy counter, with a head cold, sniffing away, and begging for some product that contains pseudoephedrine, which works like a magic nose unclogger. The stuff you can get off the shelf now contains the similar-sounding drug called phenylephrine, but it might as well be a placebo. It just doesn't work, and most everyone knows this.
You can still get the good old stuff from the pharmacist but you will be suspected for this grave action. The government, you see, says that people have been buying the old stuff and turning it into methamphetamine. This is why Congress and the administration passed the Combat Methamphetamine Epidemic Act of 2005, which rations the amount you can buy and requires that you prove your identity and sign a special form.
... Let's follow the money a bit. It seems that most all pseudoephedrine is manufactured in China and India, and very cheaply, much more cheaply than it can be made in the United States or Europe. What that means is that these companies don't have lobbyists in Washington who can make an effective case for their product.
Contrast this was phenylephrine, the world's largest manufacturer of which is located in Germany. The company is called Boehringer-Ingelheim, according to MSNBC. It developed the drug in 1949 for use in eyedrops. In the last two years, virtually every manufacturer of cold medicine has changed its formula to include the Boehringer drug. Some continue to make the old formula available but only with special access.
... If that sounds cynical, take a look at this. It seems that our friends at Boehringer Ingelheim are rather interested in American politics, with 73% of its donations going to Republican candidates for federal office. You can see here that Boehringer even has a PAC located in Ridgefield, Connecticut. Someone with more time than I have ought to check to see how the people it supported for Congress voted on the act that resulted in a massive shift toward their product, and has nearly kept its competitive product off the market.